Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zoetis ( (ZTS) ) has shared an update.
On August 27, 2025, Zoetis Inc. entered into a new five-year $1.25 billion senior unsecured revolving credit facility with a syndicate of banks, replacing its previous credit agreement. This new credit facility allows Zoetis to potentially increase its borrowing capacity to $1.75 billion, providing the company with greater financial flexibility to support its operations and strategic initiatives.
The most recent analyst rating on (ZTS) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.
Spark’s Take on ZTS Stock
According to Spark, TipRanks’ AI Analyst, ZTS is a Outperform.
Zoetis’ strong financial performance and positive earnings call are the primary drivers of its stock score. The company’s strategic execution and raised guidance underscore confidence in sustained growth. Technical indicators suggest a balanced momentum, while the valuation reflects a premium pricing. Despite some operational challenges, Zoetis remains well-positioned for future growth.
To see Spark’s full report on ZTS stock, click here.
More about Zoetis
Zoetis Inc. operates in the animal health industry, providing a wide range of medicines, vaccines, and diagnostic products for pets and livestock. The company focuses on enhancing animal care and productivity, positioning itself as a leader in the global animal health market.
Average Trading Volume: 3,168,027
Technical Sentiment Signal: Sell
Current Market Cap: $68.6B
For an in-depth examination of ZTS stock, go to TipRanks’ Overview page.